Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)

被引：0

作者：

Garcia-Manero, G.

Yang, A. S.

Klimek, V.

Luger, S.

Newsome, W. M.

Berman, N.

Patterson, T.

Maroun, C.

Li, Z.

Ward, R.

Martell, R.

机构：

[1] UT MD Anderson Canc Ctr, Houston, TX USA

[2] Norris Cromprenhens Canc Ctr, Los Angeles, CA USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA

[5] MethylGene, Montreal, PQ, Canada

[6] Pharmion, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7062

引用

页数：1

共 50 条

[41] A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
Ong, Faustine
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
Alvarado, Yesid
Ohanian, Maro
Konopleva, Marina
Jabbour, Elias
Jain, Nitin
Borthakur, Gautam
DiNardo, Courtney D.
Daver, Naval
Issa, Ghayas C.
Sasaki, Koji
Chien, Kelly S.
Takahashi, Koichi
Andreeff, Michael
Muftuoglu, Muharrem
Delumpa, Ricardo
Mayor, Ejiroghene
Loiselle, Christopher
Waller, Lourdes
Banks, Glenda
Kantarjian, Hagop
Cortes, Jorge E.
Short, Nicholas
BLOOD, 2022, 140 : 6206 - 6208
[42] Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Morita, Kiyomi
Naqvi, Kiran
Montalban, Guillermo
Thompson, Philip A.
Takahashi, Koichi
Alvarado, Yesid
Jabbour, Elias
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[43] A Phase I Trial of the Epigenetic Modulators Vorinostat, in Combination with Azacitidine (azaC) in Patients with the Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): A Study of the New York Cancer Consortium
Silverman, Lewis R.
Verma, Amit
Odchimar-Reissig, Rosalie
LeBlanc, Amanda
Najfeld, Vesna
Gabrilove, Janice
Isola, Luis
Espinoza-Delgado, Igor
Zwiebel, James
BLOOD, 2008, 112 (11) : 1252 - 1252
[44] Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G Bug
A Burchert
E-M Wagner
N Kröger
T Berg
S Güller
S K Metzelder
A Wolf
S Hünecke
P Bader
J Schetelig
H Serve
O G Ottmann
Leukemia, 2017, 31 : 2523 - 2525
[45] Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Bug, G.
Burchert, A.
Wagner, E-M
Kroeger, N.
Berg, T.
Gueller, S.
Metzelder, S. K.
Wolf, A.
Huenecke, S.
Bader, P.
Schetelig, J.
Serve, H.
Ottmann, O. G.
LEUKEMIA, 2017, 31 (11) : 2523 - 2525
[46] Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Pemmaraju, Naveen
Bhalla, Kapil N.
Daver, Naval
Wilson, Nathaniel R.
Fiskus, Warren C.
Ravandi, Farhad
Garcia-Manero, Guillermo
Kadia, Tapan M.
DiNardo, Courtney D.
Jabbour, Elias J.
Burger, Jan A.
Short, Nicholas J.
Alvarado, Yesid
Jain, Nitin
Masarova, Lucia
Verstovsek, Srdan
Issa, Ghayas C.
Qiao, Wei
Khoury, Joseph D.
Pierce, Sherry A.
Miller, Darla
Konopleva, Marina
Kantarjian, Hagop
Borthakur, Gautam
BLOOD, 2021, 138
[47] A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Assouline, Sarit
Michaelis, Laura C.
Othus, Megan
Hay, Annette E.
Walter, Roland B.
Jacoby, Meagan A.
Schroeder, Mark A.
Uy, Geoffrey L.
Law, Lisa Y.
Cheema, Faisal
Sweet, Kendra L.
Asch, Adam S.
Liu, Jijun
Moseley, Anna B.
Maher, Tracy
Kingsbury, Laura L.
Fang, Min
Radich, Jerald
Little, Richard F.
Erba, Harry P.
LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 473 - 477
[48] Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).
Garcia-Manero, Guillermo
Tambaro, Francesco Paolo
Bekele, B. Nebiyou
Jabbour, Elias
Ravandi, Farhad
Yang, Hui
Borthakur, Gautam
Kadia, Tapan
Cortes, Jorge
Faderl, Stefan
Konopleva, Marina
Pierce, Sherry
Burger, Jan A.
Estrov, Zeev
O'Brien, Susan
Thomas, Deborah
Newsome, Willie
Kantarjian, Hagop
BLOOD, 2009, 114 (22) : 436 - 436
[49] Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities
Garcia-Manero, Guillermo
Estey, Elihu H.
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Naqvi, Kiran
Levine, Ross L.
Estrov, Zeev
Quintas-Cardama, Alfonso
Konopleva, Marina
Faderl, Stefan
Tanaka, Maria
Yang, Hui
Ravandi, Farhad
Wierda, William G.
Cortes, Jorge E.
Boone, Patricia Ann
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 279 - 279
[50] Phase II study of pevonedistat (P) plus azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Ades, Lionel
Watts, Justin M.
Radinoff, Atanas
Arnan, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua F.
Diez-Campelo, Maria
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Faller, Douglas, V
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →